Transgenic mouse models of amyotrophic lateral sclerosis

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1762, Issue 11-12, 2006, Pages 1013-1024

  Julien, Jean Pierre ^a   Kriz, Jasna ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Mutant SOD1; Sclerosis; Toxicity

Indexed keywords

AEOL 10150; ALPHA TOCOPHEROL; AMYOTROPHIC LATERAL SCLEROSIS PROTEIN 2; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE INHIBITOR; CEFTRIAXONE; CELECOXIB; CHROMOGRANIN; CILIARY NEUROTROPHIC FACTOR; COPPER; COPPER ZINC SUPEROXIDE DISMUTASE; DYNEIN ADENOSINE TRIPHOSPHATASE; GABAPENTIN; GENE PRODUCT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; INTERMEDIATE FILAMENT PROTEIN; KINESIN; MINOCYCLINE; MUTANT PROTEIN; NIMODIPINE; PERIPHERIN; PORPHYRIN DERIVATIVE; RECOMBINANT VASCULOTROPIN; RILUZOLE; SALICYLIC ACID; SOMATOMEDIN C; TAU PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

AMYOTROPHIC LATERAL SCLEROSIS; CATALYSIS; CLINICAL TRIAL; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; GENE DISRUPTION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; KNOCKOUT MOUSE; MICROTUBULE; MOTOR NEURON DISEASE; MOUSE STRAIN; NERVE CELL; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW; SIGNAL PROCESSING; TRANSGENIC MOUSE; TREATMENT OUTCOME; VIRAL GENE THERAPY;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; INTERMEDIATE FILAMENTS; MICE; MICE, TRANSGENIC; MICROTUBULES; MODELS, NEUROLOGICAL; MOTOR NEURONS; MUTATION; SUPEROXIDE DISMUTASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS MUSCULUS;

EID: 33751013740     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2006.03.006     Document Type: Review

References (131)

1. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J.P., Deng H.X., Rahmani Z., Krizus A., McKenna-Yasek D., Cayabyab A., Gaston S.M., Berger R., Tanzi R.E., Halperin J.J., Herzfeldt B., Van den Bergh R., Hung W.Y., Bird T., Deng G., Mulder D.W., Smyth C., Laing N.G., Soriano E., Pericak-Vance M.A., Haines J., Rouleau G.A., Gusella J.S., Horvitz H.R., and Brown Jr. R.H. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362 (1993) 59-62
2. Julien J.P. Amyotrophic lateral sclerosis: unfolding the toxicity of the misfolded. Cell 104 (2001) 581-591
3. Cleveland D.W. From Charcot to SOD1: mechanisms of selective motor neuron death in ALS. Neuron 24 (1999) 515-520
4. Reaume A.B., Elliott J.L., Hoffman E.K., Kowall N.W., Ferrante R.J., et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat. Genet. 13 (1996) 43-47
5. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A.A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human CuZn superoxide dismutase mutation. Science 264 (1994) 1772-1775
6. Wong P.C., Pardo C.A., Borchelt D.R., Lee M.K., Copeland N.G., Jenkins N.A., Sisodia S.S., Cleveland D.W., and Price D.L. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14 (1994) 1105-1116
7. Bruijn L.I., Houseweart M.K., Kato S., Anderson K.L., Anderson S.D., Ohama E., Reaume A.G., Scott R.W., and Cleveland D.W. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18 (1997) 327-338
8. Wiedau-Pazos M., Goto J.J., Rabizadeh S., Gralla E.D., Roe J.A., Valentine J.S., and Bredesen D.E. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science 271 (1996) 515-518
9. Beckman J.S., Carson M., Smith C.D., and Koppenol W.H. ALS, SOD and peroxynitrite. Nature 364 (1993) 584
10. Bruijn L.I., Houseweart M.K., Kato S., Anderson K.L., Anderson S.D., Ohama E., Reaume A.G., Scott R.W., and Cleveland D.W. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281 (1998) 1851-1854
11. Subramaniam J.R., Lyons W.E., Liu J., Bartnikas T.B., Rothstein J., Price D.L., Cleveland D.W., Gitlin J.D., and Wong P.C. Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading. Nat. Neurosci. 5 (2002) 301-307
12. Wang J., Xu G., Gonzales V., Coonfield M., Fromholt D., Copeland N.G., Jenkins N.A., and Borchelt D.R. Fibrillar inclusions and motor neuron degeneration in transgenic mice expressing superoxide dismutase 1 with a disrupted copper-binding site. Neurobiol. Dis. 10 (2002) 128-138
13. Durham H.D., Roy J., Dong L., and Figlewicz D.A. Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. J. Neuropathol. Exp. Neurol. 56 (1997) 52-56
14. Johnston J.F., Dalton M.J., Gurney M.E., and Kopito R.R. Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 12571-12576
15. Bruening W., Roy J., Giasson B., Figlewicz D.A., Mushynski W.E., and Durham H.D. Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated with amyotrophic lateral sclerosis. J. Neurochem. 72 (1999) 693-699
16. Batulan Z., Shinder G.A., Minotti S., He B.P., Doroudchi M.M., Nalbantoglu J., Strong M.J., and Durham H.D. High threshold for induction of the stress response in motor neurons is associated with failure to activate HSF1. J. Neurosci. 23 (2003) 5789-5798
17. Urushitani M., Kurisu J., Tsukita K., and Takahashi R. Proteasomal inhibition by misfolded mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral sclerosis. J. Neurochem. 83 (2002) 1030-1042
18. Liu J., Shinobu L.A., Ward C.M., Young D., and Cleveland D.W. Elevation of the Hsp70 chaperone does not effect toxicity in mouse models of familial amyotrophic lateral sclerosis. J. Neurochem. 93 (2005) 875-882
19. Liu J., Lillo C., Jonsson P.A., Vande Velde C., Ward C.M., Miller T.M., Subramaniam J.R., Rothstein J.D., Marklund S., Andersen P.M., Brannstrom T., Gredal O., Wong P.C., Williams D.S., and Cleveland D.W. Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron 43 (2004) 5-17
20. Pasinelli P., Belford M.E., Lennon N., Bacskai B., Hyman B.T., Trotti D., and Brown Jr. R.H. Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron 43 (2004) 19-30
21. Raoul C., Estevez A.G., Nishimune H., Cleveland D.W., deLapeyriere O., Henderson C.E., Haase G., and Pettmann B. Motoneuron death triggered by a specific pathway downstream of Fas, Potentiation by ALS-linked SOD1 mutations. Neuron 35 (2002) 1067-1083
22. Nguyen M.D., Lariviere R.C., and Julien J.-P. Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. Neuron 30 (2001) 135-147
23. Nguyen M.D., Boudreau M., Kriz J., Couillard-Despres S., Kaplan D.R., and Julien J.-P. Cell cycle regulators in the neuronal death pathway of amyotrophic lateral sclerosis caused by mutant superoxide dismutase 1. J. Neurosci. 23 (2003) 2131-2140
24. Patrick G.N., Zukerberg L., Nikolic M., de la Monte S., Dikkes P., and Tsai L.H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402 (1999) 615-622
25. Park D.S., Morris E.J., Stefanis L., Troy C.M., Shelanski M.L., Geller H.M., and Greene L.A. Multiple pathways of neuronal death induced by DNA-damaging agents NGF deprivation, and oxidative stress. J. Neurosci. 18 (1998) 830-840
26. Takahashi S., and Kulkarni A.B. Mutant superoxide dismutase 1 causes motor neuron degeneration independent of cyclin-dependent kinase 5 activation by p35 or p25. J. Neurochem. 88 (2004) 1295-1304
27. Lobsiger C.S., Garcia M.L., Ward C.M., and Cleveland D.W. Altered axonal architecture by removal of the heavily phosphorylated neurofilament tail domains strongly slows superoxide dismutase 1 mutant-mediated ALS. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 10351-10356
28. Zhang B., Tu P., Abtahian F., Trojanowski J.Q., and Lee V.M. Neurofilaments and orthograde transport are reduced in ventral root axons of transgenic mice that express human SOD1 with a G93A mutation. J. Cell Biol. 139 (1997) 1307-1315
29. Williamson T.L., and Cleveland D.W. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat. Neurosci. 2 (1999) 50-56
30. Jonsson P.A., Graffmo K.S., Andersen P.M., Brannstrom T., Lindberg M., Oliveberg M., and Marklund S. Disulphide-reduced superoxide dismutase-1 in CNS of transgenic amyotrophic lateral sclerosis models. Brain (2005) (on line)
31. Wang J., Xu G., Li H., Gonzales V., Fromholt D., Karch C., et al. Somatodendritic accumulation of misfolded SOD1-L126Z in motor neurons mediates degeneration: αB-crystallin modulates aggregation. Hum. Mol. Genet. 14 (2005) 2335-2347
32. Fischer L.R., Culver D.G., Tennant P., Davis A.A., Wang M., Castellano-Sanchez A., Khan J., Polak M.A., and Glass J.D. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol. 185 (2004) 232-240
33. Howland D.S., Liu J., She Y., Goad B., Maragakis N.J., Kim B., Erickson J., Kulik J., DeVito L., Psaltis G., DeGennaro L.J., Cleveland D.W., and Rothstein J.D. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 1604-1609
34. Nguyen M.D., Julien J.-P., and Rivest S. Induction of proinflammatory molecules in mice with amyotrophic lateral sclerosis: no requirement for proapoptotic interleukin-1beta in neurodegeneration. Ann. Neurol. 50 (2001) 630-639
35. Nguyen M.D., D'Aigle T., Gowing G., Julien J.-P., and Rivest S. Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. 24 (2004) 1340-1349
36. Kriz J., Nguyen M.D., and Julien J.-P. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 10 (2002) 268-278
37. Drachman D.B., Frank K., Dykes-Hoberg M., Teismann P., Almer G., Przedborski S., and Rothstein J.D. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. 52 (2002) 771-778
38. Gong Y.H., Parsadanian A.S., Andreeva A., Snider W.D., and Elliott J.L. Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J. Neurosci. 20 (2000) 660-665
39. Wang J., Xu G., Slunt H.H., Gonzales V., Coonfield M., Fromholt D., Copeland N.G., Jenkins N.A., and Borchelt D.R. Coincident thresholds of mutant protein for paralytic disease and protein aggregation caused by restrictively expressed superoxide dismutase cDNA. Neurobiol. Dis. 20 (2005) 943-952
40. Pramatarova A., Laganiere J., Roussel J., Brisebois K., and Rouleau G.A. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J. Neurosci. 21 (2001) 3369-3374
41. Lino M.M., Schneider C., and Caroni P. Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J. Neurosci. 22 (2002) 4825-4832
42. Clement A.M., Nguyen M.D., Roberts E.A., Doucette W., Ferrante R., McMahon A., Brown Jr. R.H., Julien J.-P., Goldstein L.S.B., and Cleveland D.W. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 302 (2003) 113-117
43. Urushitani M., Sik A., Sakurai T., Nukina N., Takahashi R., and Julien J.-P. Chromogranin-mediated secretion of ALS-linked superoxide dismutase mutants as a novel pathogenic pathway for ALS. Nat. Neurosci. 9 (2006) 108-118
44. Hirano A., Nakano I., Kurland L.T., Mulder D.W., Holley P.W., and Saccomanno G. Fine structural study of neurofibrillary changes in a family with amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 43 (1984) 471-480
45. Corbo M., and Hays A.P. Peripherin and neurofilament protein coexist in spinal spheroids of motor neuron disease. J. Neuropathol. Exp. Neurol. 51 (1992) 531-537
46. Lariviere R., and Julien J.-P. Functions of intermediate filaments in neuronal development and disease. J. Neurobiol. 58 (2004) 131-148
47. Mersiyanova I.V., Perepelov A.V., Polyakov A.V., Sitnikov V.F., Dadali E.L., Oparin R.B., Petrin A.N., and Evgrafov O.V. A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. Am. J. Hum. Genet. 67 (2000) 37-46
48. De Jonghe P., Mersiyanova I.V., Nelis E., Del Favero J., Martin J.J., Van Broeckhoven C., Evgrafov O.V., and Timmerman V. Further evidence that neurofilament light chain mutations can cause Charcot-Marie-Tooth disease type 2E. Ann. Neurol. 49 (2001) 245-249
49. Gros-Louis F., Lariviere R., Gowing G., Laurent S., Camu W., Bouchard J.-P., Meininger V., Rouleau G.A., and Julien J.-P. A frameshift deletion in peripherin gene associated with amyotrophic lateral sclerosis. J. Biol. Chem. 279 (2004) 45951-45956
50. Zhu Q., Couillard-Despres S., and Julien J.-P. Delayed maturation of regenerating myelinated axons in mice lacking neurofilaments. Exp. Neurol. 148 (1997) 299-316
51. Rao M.V., Houseweart M.K., Williamson T.L., Crawford T.O., Folmer J., and Cleveland D.W. Neurofilament-dependent radial growth of motor axons and axonal organization of neurofilaments does not require the neurofilament heavy subunit (NF-H) or its phosphorylation. J. Cell Biol. 143 (1998) 171-181
52. Elder G.A., Friedrich V.L., Kang Jr. C., Bosco P., Gourov A., Tu P.H., Zhang B., Lee V.M., and Lazzarini R.A. Requirement of heavy neurofilament subunit in the development of axons with large calibers. J. Cell Biol. 143 (1998) 195-205
53. Elder G.A., Friedrich V.L., Margita Jr. A., and Lazzarini R.A. Age-related atrophy of motor axons in mice deficient in the mid-sized neurofilament subunit. J. Cell Biol. 146 (1999) 181-192
54. Levavasseur F., Zhu Q., and Julien J.-P. No requirement of alpha-internexin for nervous system development and for radial growth of axons. Brain Res. Mol. Brain Res. 69 (1999) 104-112
55. Jacomy H., Zhu Q., Couillard-Despres S., Beaulieu J.M., and Julien J.-P. Disruption of type IV intermediate filament network in mice lacking the neurofilament medium and heavy subunits. J. Neurochem. 73 (1999) 972-984
56. Kriz J., Zhu Q., Julien J.-P., and Padjen A.L. Electrophysiological properties of axons in mice lacking neurofilament subunit genes: disparity between conduction velocity and axon diameter in absence of NF-H. Brain Res. 885 (2000) 32-44
57. Dubois M., Strazielle C., Julien J.-P., and Lalonde R. Mice with the deleted neurofilament of low molecular weight (Nefl) gene: 2, Effects on motor functions and spatial orientation. J. Neurosci. Res. 80 (2005) 751-758
58. Dubois M., Lalonde R., Julien J.-P., and Strazielle C. Mice with the deleted neurofilament of low-molecular-weight (Nefl) gene: 1, Effects on regional brain metabolism. J. Neurosci. Res. 80 (2005) 741-750
59. Larivière R., Nguyen M.D., Ribeiro-da-Silva A., and Julien J.-P. Reduced number of unmyelinated sensory axons in peripherin null mice. J. Neurochem. 81 (2002) 525-532
60. Cote F., Collard J.-F., and Julien J.-P. Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral sclerosis. Cell 73 (1993) 35-46
61. Xu Z., Cork L.C., Griffin J.W., and Cleveland D.W. Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease. Cell 73 (1993) 23-33
62. Meier J., Couillard-Després S., and Julien J.-P. Extra neurofilament NF-L proteins rescue motor neuron disease caused by overexpression of human NF-H in mice. J. Neuropathol. Exp. Neurol. 58 (1999) 1099-1110
63. Kriz J., Meier J., Julien J.-P., and Padjen A.L. Altered ionic conductances in axons of transgenic mice expressing the human neurofilament heavy gene. Exp. Neurol. 163 (2000) 414-421
64. Lee M.K., Marszalek J.R., and Cleveland D.W. A mutant neurofilament subunit causes massive, selective motor neuron death: implications for the pathogenesis of human motor neuron disease. Neuron 13 (1994) 975-988
65. Houseweart M.K., and Cleveland D.W. Bcl-2 overexpression does not protect neurons from mutant neurofilament-mediated motor neuron degeneration. J. Neurosci. 19 (1999) 6446-6456
66. Beaulieu J.M., Nguyen M.D., and Julien J.-P. Late onset death of motor neurons in mice overexpressing wild-type peripherin. J. Cell Biol. 147 (1999) 531-544
67. Beaulieu J.M., Jacomy H., and Julien J.-P. Formation of intermediate filament protein aggregates with disparate effects in two transgenic mouse models lacking the neurofilament light subunit. J. Neurosci. 20 (2000) 5321-5328
68. Wong N.K.Y., He B.P., and Strong M.J. Characterization of neuronal intermediate filament protein expression in cervical spinal motor neurons in sporadic amyotrophic lateral sclerosis (ALS). J. Neuropathol. Exp. Neurol. 59 (2000) 972-982
69. Beaulieu J.M., and Julien J.-P. Peripherin-mediated death of motor neurons rescued by overexpression of neurofilament NF-H proteins. J. Neurochem. 85 (2003) 248-256
70. Robertson J., Beaulieu J.M., Doroudchi M.M., Durham H.D., Julien J.-P., and Mushynski W.E. Apoptotic death of neurons exhibiting peripherin aggregates is mediated by the proinflammatory cytokine tumor necrosis factor-alpha. J. Cell Biol. 155 (2001) 217-226
71. Larivière R., Beaulieu J.M., Nguyen M.D., and Julien J.-P. Peripherin is not a contributing factor to motor neuron disease in a mouse model of ALS caused by mutant superoxide dismutase. Neurobiol. Dis. 13 (2003) 158-166
72. Robertson J., Doroudchi M.M., Nguyen M.D., Durham H.D., Strong M.J., Shaw G., Julien J.-P., and Mushynski W.E. A neurotoxic peripherin splice variant in a mouse model of ALS. J. Cell Biol. 160 (2003) 939-949
73. Zhao C., Takita J., Tanaka Y., Setou M., Nakagawa T., Takeda S., Yang H.W., Terada S., Nakata T., Takei Y., Saito M., Tsuji S., Hayashi Y., and Hirokawa N. Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta. Cell 105 (2001) 587-597
74. Reid E., Kloos M., Ashley-Koch A., Hughes L., Bevan S., Svenson I.K., Gaskell P.C., Dearlove A., Pericak-Vance M.A., Rubinsztein D.C., and Marchuk D.A. A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am. J. Hum. Genet. 71 (2002) 1189-1194
75. Xia C.H., Roberts E.A., Her L.S., Liu X., Williams D.S., Cleveland D.W., and Goldstein L.S. Abnormal neurofilament transport caused by targeted disruption of neuronal kinesin heavy chain KIF5A. J. Cell Biol. 161 (2003) 55-66
76. Schroer T.A. Dynactin. Annu. Rev. Cell Dev. Biol. 20 (2004) 759-779
77. LaMonte B.H., Wallace K.E., Holloway B.A., Shelly S.S., Ascano J., Tokito M., Van Winkle T., Howland D.S., and Holzbaur E.K. Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron 34 (2002) 715-727
78. Hafezparast M., Klocke R., Ruhrberg C., Marquardt A., Ahmad-Annuar A., Bowen S., Lalli G., Witherden A.S., Hummerich H., Nicholson S., Morgan P.J., Oozageer R., Priestley J.V., Averill S., King V.R., Ball S., Peters J., Toda T., Yamamoto A., Hiraoka Y., Augustin M., Korthaus D., Wattler S., Wabnitz P., Dickneite C., Lampel S., Boehme F., Peraus G., Popp A., Rudelius M., Schlegel J., Fuchs H., Hrabe de Angelis M., Schiavo G., Shima D.T., Russ A.P., Stumm G., Martin J.E., and Fisher E.M. Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science 300 (2003) 808-812
79. Puls I., Jonnakuty C., LaMonte B.H., Holzbaur E.L., Tokito M., Mann E., Floeter M.K., Bidus K., Drayna D., Oh S.J., Brown Jr. R.H., Ludlow C.L., and Fischbeck K.H. Mutant dynactin in motor neuron disease. Nat. Genet. 33 (2003) 455-456
80. Bommel H., Xie G., Rossoll W., Wiese S., Jablonka S., Boehm T., and Sendtner M. Missense mutation in the tubulin-specific chaperone E (Tbce) gene in the mouse mutant progressive motor neuronopathy, a model of human motoneuron disease. J. Cell Biol. 159 (2002) 563-569
81. Martin N., Jaubert J., Gounon P., Salido E., Haase G., Szatanik M., and Guenet J.L. A missense mutation in Tbce causes progressive motor neuronopathy in mice. Nat. Genet. 32 (2002) 443-447
82. Lee V.M., Goedert M., and Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24 (2001) 1121-1159
83. Ishihara T., Hong M., Zhang B., Nakagawa Y., Lee M.K., Trojanowski J.Q., and Lee V.M. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24 (1999) 751-762
84. Trojanowski J.Q., Ishihara T., Higuchi M., Yoshiyama Y., Hong M., Zhang B., Forman M.S., Zhukareva V., and Lee V.M. Amyotrophic lateral sclerosis/parkinsonism dementia complex: transgenic mice provide insights into mechanisms underlying a common tauopathy in an ethnic minority on Guam. Exp. Neurol. 176 (2002) 1-11
85. Ishihara T., Higuchi M., Zhang B., Yoshiyama Y., Hong M., Trojanowski J.Q., and Lee V.M. Attenuated neurodegenerative disease phenotype in tau transgenic mouse lacking neurofilaments. J. Neurosci. 21 (2001) 6026-6035
86. Oosthuyse B., Moons L., Storkebaum E., Beck H., Nuyens D., Brusselmans K., Van Dorpe J., Hellings P., Gorselink M., Heymans S., Theilmeier G., Dewerchin M., Laudenbach V., Vermylen P., Raat H., Acker T., Vleminckx V., Van Den Bosch L., Cashman N., Fujisawa H., Drost M.R., Sciot R., Bruyninckx F., Hicklin D.J., Ince C., Gressens P., Lupu F., Plate K.H., Robberecht W., Herbert J.M., Collen D., and Carmeliet P. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 28 (2001) 131-138
87. Lambrechts D., Storkebaum E., Morimoto M., Del-Favero J., Desmet F., Marklund S.L., Wyns S., Thijs V., Andersson J., van Marion I., Al-Chalabi A., Bornes S., Musson R., Hansen V., Beckman L., Adolfsson R., Pall H.S., Prats H., Vermeire S., Rutgeerts P., Katayama S., Awata T., Leigh N., Lang-Lazdunski L., Dewerchin M., Shaw C., Moons L., Vlietinck R., Morrison K.E., Robberecht W., Van Broeckhoven C., Collen D., Andersen P.M., and Carmeliet P. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat. Genet. 34 (2003) 383-394
88. Terry P.D., Kamel F., Umbach D.M., Lehman T.A., Hu H., Sandler D.P., and Taylor J.A. VEGF promoter haplotype and amyotrophic lateral sclerosis (ALS). J. Neurogenet. 18 (2004) 429-434
89. Moreau C., Devos D., Brunaud-Danel V., Defebvre L., Perez T., et al. Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS. J. Neurol. Neurosurg. Psychiatry 77 (2006) 255-257
90. Pioro E.P., Wang Y., Moore J.K., Ng T.C., Trapp B.D., Klinkosz B., and Mitsumoto H. Neuronal pathology in the wobbler mouse brain revealed by in vivo proton magnetic resonance spectroscopy and immunocytochemistry. NeuroReport 9 (1998) 3041-3046
91. Xu G.-P., Dave K.R., Moraes C.T., Busto R., Sick T.J., Bradley W.G., and Pérez-Pinzón M.A. Dysfunctional mitochondrial respiration in the wobbler mouse brain. Neurosci. Lett. 300 (2001) 141-144
92. Pernas-Alonso R., Perrone-Capano C., Volpicelli F., and di Porzio U. Neurofilament accumulation and motoneuron degeneration are linked phenotypes in Wobbler neuromuscular disease. Neurobiol. Dis. 8 (2001) 581-589
93. Hadano S., Hand C.K., Osuga H., Yanagisawa Y., Otomo A., Devon R.S., Miyamoto N., Showguchi-Miyata J., Okada Y., Singaraja R., Figlewicz D.A., Kwiatkowski T., Hosler B.A., Sagie T., Skaug J., Nasir J., Brown Jr. R.H., Scherer S.W., Rouleau A.G., Hayden M.R., and Ikeda J.E. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat. Genet. 29 (2001) 166-173
94. Yang Y., Hentati A., Deng H.X., Dabbagh O., Sasaki T., Hirano M., Hung W.Y., Ouahchi K., Yan J., Azim A.C., Cole N., Gascon G., Yagmour A., Ben-Hamida M., Pericak-Vance M., Hentati F., and Siddique T. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat. Genet. 29 (2001) 160-165
95. Eymard-Pierre E., Lesca G., Dollet S., Santorelli F.M., di Capua M., Bertini E., and Boespflug-Tanguy O. Infantile-onset ascending hereditary spastic paralysis is associated with mutations in the Alsin gene. Am. J. Hum. Genet. 71 (2002) 518-527
96. Gros-Louis F., Meijer I.A., Hand C.K., Dube M.P., MacGregor D.L., Seni M.H., Devon R.S., Hayden M.R., Andermann F., Andermann E., and Rouleau G.A. An ALS2 gene mutation causes hereditary spastic paraplegia in a Pakistani kindred. Ann. Neurol. 53 (2003) 144-145
97. Cai H., Lin X., Xie C., Laird F.M., Lai C., Wen H., Chiang H.C., Shim H., Farah M.H., Hoke A., Price D.L., and Wong P.C. Loss of ALS2 function is insufficient to trigger motor neuron degeneration in knock-out mice but predisposes neurons to oxidative stress. J. Neurosci. 25 (2005) 7567-7574
98. Hadano S., Benn S.C., Kakuta S., Otomo A., Sudo K., et al. Mice deficient in the Rab5 guanine nucleotide exchange factor ALS2/alsin exhibit age-dependent neurological deficits and altered endosome trafficking. Hum. Mol. Genet. 15 (2006) 233-250
99. Gurney M.E., Cutting F.B., Zhai P., Doble A., Taylor C.P., Andrus P.K., and Hall E.D. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 39 (1996) 147-157
100. Gurney M.E., Fleck T.J., Himes C.S., and Hall E.D. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology 50 (1998) 62-66
101. Barneoud P., and Curet O. Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis. Exp. Neurol. 155 (1999) 243-251
102. Li M., Ona V.O., Guegan C., Chen M., Jackson-Lewis V., Andrews L.J., Olszewski A.J., Stieg P.E., Lee J.P., Przedborski S., and Friedlander R.M. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 288 (2000) 335-339
103. Zhu S., Stavrovskaya G., Drozda M., Kim B.Y., Ona V., Li M., Sarang S., Liu A.S., Hartley D.M., Wu Du C., Gullans S., Ferrante R.J., Przedborski S., Kristal B.S., and Friedlander R.M. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417 (2002) 74-78
104. Van Den Bosch L., Tilkin P., Lemmens G., and Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 13 (2002) 1067-1070
105. Kriz J., Gowing G., and Julien J.P. Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann. Neurol. 53 (2003) 429-436
106. Rothstein J.D., Patel S., Regan M.R., Haenggeli C., Huang Y.H., Bergles D.E., Jin L., Dykes Hoberg M., Vidensky S., Chung D.S., Toan S.V., Bruijn L.I., Su Z.Z., Gupta P., and Fisher P.B. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433 (2005) 73-77
107. Crow J.P., Calingasan N.Y., Chen J., Lynch Hill J., and Beal M.F. Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann. Neurol. 58 (2005) 258-265
108. Storkebaum E., Lambrechts D., Dewerchin M., Moreno-Murciano M.-P., Appelsman S., et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat. Neurosci. 8 (2004) 85-92
109. Wang L.J., Lu Y.Y., Muramatsu S., Ikeguchi K., Fujimoto K., Okada T., Mizukami H., Matsushita T., Hanazono Y., Kume A., Nagatsu T., Ozawa K., and Nakano I. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J. Neurosci. 22 (2002) 6920-6928
110. Kaspar B.K., Llado J., Sherkat N., Rothstein J.D., and Gage F.H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301 (2003) 839-842
111. Azzouz M., Ralph G.S., Storkebaum E., Walmsley L.E., Mitrophanous K.A., Kingsman S.M., Carmeliet P., and Mazarakis N.D. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429 (2004) 413-417
112. Ralph G.S., Radcliffe P.A., Day D.M., Carthy J.M., Leroux M.A., Lee D.C., Wong L.F., Bilsland L.G., Greensmith L., Kingsman S.M., Mitrophanous K.A., Mazarakis N.D., and Azzouz M. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med. 11 (2005) 429-433
113. Raoul C., Abbas-Terki T., Bensadoun J.C., Guillot S., Haase G., Szulc J., Henderson C.E., and Aebischer P. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med. 11 (2005) 423-428
114. Miller T.M., Kaspar B.K., Kops G.J., Yamanaka K., Christian L.J., Gage F.H., and Cleveland D.W. Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Ann. Neurol. 57 (2005) 773-776
115. Klivenyi P., Ferrante R.J., Matthews R.T., Bogdanov M.B., Klein A.M., Andreassen O.A., Meuller G., Wermer M., Kaddurah-Daouk R., and Beal M.F. Neuroprotective effects of creatin in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. 5 (1999) 347-350
116. Zhang W., Narayanan M., and Friedlander R.M. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann. Neurol. 53 (2003) 267-270
117. Groeneveld G.J., Veldink J.H., and van der Tweel I. A randomized sequential trial of creatine monohydrate in amyotrophic lateral sclerosis. Ann. Neurol. 53 (2003) 437-445
118. Sendtner M. Damaging secretions: chromogranins team up with mutant SOD1. Nat. Neurosci. 9 (2006) 12-14
119. Giasson B.I., Duda J.E., Quinn S.M., Zhang N., Trojanowski J.Q., and Lee V.M. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34 (2002) 521-533
120. Bian F., Nath R., Sobocinski G., Booher R.N., Lipinski W.J., Callahan M.J., Pack A., Wang K.K., and Walker L.C. Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice. J. Comp. Neurol. 446 (2002) 257-266
121. Jiang F., DeSilva S., and Turnbull J. Beneficial effect of ginseng root in SOD-1 (G93A) transgenic mice. J. Neurol. Sci. 180 (2000) 52-54
122. Turner B.J., Atkin J.D., Farg M.A., Zang da W., Rembach A., Lopes E.C., Patch J.D., Hill A.F., and Cheema S.S. Impaired extracellular secretion of mutant superoxide dismutase 1 associates with neurotoxicity in familial amyotrophic lateral sclerosis. J. Neurosci. 25 (2005) 108-117
123. Wang L.J., Lu Y.Y., Muramatsu S., Ikeguchi K., Fujimoto K., Okada T., Mizukami H., Matsushita T., Hanazono Y., Kume A., Nagatsu T., Ozawa K., and Nakano I. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J. Neurosci. 22 (2002) 6920-6928
124. Bordet T., Lesbordes J.C., Rouhani S., Castelnau-Ptakhine L., Schmalbruch H., Haase G., and Kahn A. Protective effects of cardiotrophin-1 adenoviral gene transfer on neuromuscular degeneration in transgenic ALS mice. Hum. Mol. Genet. 10 (2001) 1925-1933
125. Couillard-Després J.-S., Zhu Q., Wong P.C., Price D.L., Cleveland D.W., and Julien J.-P. Protective effect of neurofilament NF-H overexpression in motor neuron disease induced by mutant superoxide dismutase. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 9626-9630
126. Kostic V., Jackson-Lewis V., de Bilbao F., Dubois-Dauphin M., and Przedborski S. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 277 (1997) 559-562
127. Friedlander R.M., Brown R.H., Gagliardini V., Wang J., and Yuan J. Inhibition of ICE slows ALS in mice. Nature 388 (1997) 31
128. Williamson T.L., Bruijn L.I., Zhu Q., Anderson K.L., Anderson S.D., Julien J.P., and Cleveland D.W. Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 9631-9636
129. Facchinetti F., Sasaki M., Cutting F.B., Zhai P., MacDonald J.E., Reif D., Beal M.F., Huang P.L., Dawson T.M., Gurney M.E., Dawson V.L., et al. Lack of involvement of neuronal nitric oxide synthase in the pathogenesis of a transgenic mouse model of familial amyotrophic lateral sclerosis. Neuroscience 90 (1999) 1483-1492
130. Barneoud P., and Curet O. Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis. Exp. Neurol. 155 (1999) 243-251
131. Chung J., Yang H., de Beus M.D., Ryu C.Y., Cho K., and Colon W. Cu/Zn superoxide dismutase can form pore-like structures. Biochem. Biophys. Res. Commun. 312 (2003) 873-876